Information:
Fel:
ID
34329
Beskrivning
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection; ODM derived from: https://clinicaltrials.gov/show/NCT01147107
Länk
https://clinicaltrials.gov/show/NCT01147107
Nyckelord
Versioner (1)
- 2019-01-16 2019-01-16 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
16 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Hepatitis C, Chronic NCT01147107
Eligibility Hepatitis C, Chronic NCT01147107
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C, Chronic NCT01147107
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
hiv infected patients, age >18 years, meet vietnam guideline to begin art (cd4 count < 350 cells/mm3 and/or who stage iii or iv disease)
boolean
ID.2
Item
hepatitis c infection as documented by positive hcv antibodies and a detectable serum hcv rna level
boolean
ID.3
Item
ast and alt ≤ 2 x uln (≤ 80 u/l)
boolean
ID.4
Item
estimated creatinine clearance ≥ 60 ml/min
boolean
ID.5
Item
any prior art
boolean
ID.6
Item
positive hepatitis b surface antigen
boolean
ID.7
Item
clinical evidence of de-compensated cirrhosis (ascites, encephalopathy, esophageal bleeding)
boolean
ID.8
Item
requirement for acute therapy for other aids-defining illness within 14 days prior to study entry
boolean
ID.9
Item
currently on rifampicin therapy
boolean
ID.10
Item
in the first trimester of pregnancy, intent to become pregnant, or breast feeding during the study period
boolean